Encompass Health Corp (EHC) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 167 facilities across 38 states and Puerto Rico as of the reporting date. The company operates a single reportable segment focused on inpatient rehabilitation services, with significant concentrations in Florida and Texas.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Operating Revenues | $1,455.4 | $1,316.0 |
| Net Income Attributable to Encompass Health | $151.5 | $112.5 |
| Diluted EPS | $1.48 | $1.10 |
| Adjusted EBITDA | $313.6 | $273.0 |
| Operating Cash Flow | $288.6 | $238.8 |
| Total Debt (Long-term + Current) | $2,471.9 | $2,497.8 |
| Cash and Cash Equivalents | $95.8 | $69.1 |
| Capital Expenditures | $163.1 | $139.4 |
Margins: Operating expenses as a percentage of net operating revenues decreased to 81.7% in Q1 2025 from 84.2% in Q1 2024, driven by volume growth.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 10.6% year-over-year, driven by a 6.3% increase in discharges (including 4.4% same-store growth) and a 3.9% increase in net patient revenue per discharge due to higher reimbursement rates.
- Profitability: Net income attributable to Encompass Health rose 34.7% to $151.5 million. This improvement was aided by the absence of the $10.4 million impairment charge recorded in Q1 2024 related to the closure of a joint venture hospital in Eau Claire, Wisconsin.
- Cost Management: Salaries and benefits increased 7.1% but decreased as a percentage of revenue (52.4% vs. 54.1%) due to operational leverage. Interest expense decreased 9.7% to $31.8 million.
- Shareholder Returns: The company repurchased 0.3 million shares for $32.1 million and declared a quarterly dividend of $0.17 per share.
Outlook, Risks, and Management Commentary
Guidance and Outlook: Management remains optimistic about long-term demand driven by an aging population. The company expects to spend approximately $755 million to $790 million on capital expenditures in 2025. No specific full-year financial guidance was provided in this text, but the company anticipates continued volume growth and pricing increases.
Regulatory Environment:
- 2026 Proposed Rule: CMS released a proposed rule for FY2026 IRF payments. Management estimates this will result in a net increase to Medicare payment rates of approximately 2.7% effective October 1, 2025.
- Review Choice Demonstration (RCD): The company operates 48 hospitals in states subject to RCD (Alabama, Pennsylvania, Texas, California). While the company achieved validation rates in the first cycle in Alabama, it did not meet the 85% threshold in the second cycle, remaining subject to 100% pre-claim review. The financial impact of this program remains uncertain.
Risks: Key risks include changes in Medicare reimbursement, regulatory compliance (including False Claims Act/qui tam suits), staffing shortages, and the potential for increased costs due to inflation or tariffs.
Investor Verification Checklist
- Reimbursement Rates: Verify the final impact of the CMS 2026 Proposed Rule on net patient revenue per discharge once finalized.
- RCD Program Impact: Monitor the claim validation rates and cash flow implications of the 100% pre-claim review requirement in Alabama and potential expansion to other states.
- Debt Maturities: Confirm the company's ability to refinance or repay the $100 million in 5.75% Senior Notes due in 2025 and the $833 million due in 2028.
- Capital Expenditure Execution: Track the progress of de novo projects (e.g., Fort Myers, Daytona Beach) against the $755-$790 million 2025 budget.
- Staffing Costs: Assess the trend in "Employees per Occupied Bed" (EPOB) to ensure labor cost efficiency is maintained amidst volume growth.